Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.

Source: Reuters: Health - July 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news